Abstract:Adoptive immunotherapy based on chimeric antigen receptor (CAR)-engineered T cells has exhibited impressive clinical efficacy in treating B-cell malignancies. However, the potency of CAR-T cells carriethe potential for significant on-target/off-tumor toxicities when target antigens are shared with healthy cells, necessitating the development of complementary safety measures. In this context, there is a need to selectively eliminate therapeutically administered CAR-T cells, especially to revert long-term CAR-T cell-related side effects. To address this, we have developed an effective cellular-based safety mechanism to specifically target and eliminate the transferred CAR-T cells. As proof-of-principle, we have designed a secondary CAR ( anti -CAR CAR) capable of recognizing a short peptide sequence (Strep-tag II) incorporated into the hinge domain of an anti -CD19 CAR. In in vitro experiments, these anti -CAR CAR-T cells have demonstrated antigen-specific cytokine release and cytotoxicity when co-cultured with anti -CD19 CAR-T cells. Moreover, in both immunocompromised and immunocompetent mice, we observed the successful depletion of anti -CD19 CAR-T cells when administered concurrently with anti -CAR CAR-T cells. We have also demonstrated the efficacy of this safeguard mechanism in a clinically relevant animal model of B-cell aplasia induced by CD19 CAR treatment, where this side effect was reversed upon anti -CAR CAR-T cells infusion. Notably, efficient B-cell recovery occurred even in the absence of any pre-conditioning regimens prior anti -CAR CAR-T cells transfer, thus enhancing its practical applicability. In summary, we developed a robust cellular safeguard system for selective in vivo elimination of engineered T cells, offering a promising solution to address CAR-T cell-related on-target/off-tumor toxicities.

Universal protection of allogeneic T cell therapies from natural killer cells vxia CD300a agonism

Universal Protection of Allogeneic T-Cell Therapies from Natural Killer Cells via CD300a Agonism

Universal protection of allogeneic cell therapies from natural killer cells via CD300a agonism

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection

Single-Cell Heterogeneity Restorative Chimeric Engineering Nanoparticles for Alleviating Antibody-Mediated Allograft Injury.

A T-cell independent universal cellular therapy strategy through antigen depletion

Engineered off-the-shelf therapeutic T cells resist host immune rejection

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy

Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies

Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells

Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects

Costimulatory Blockade of CD154-CD40 in Combination with T-cell Lymphodepletion Results in Prevention of Allogeneic Sensitization

Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming

Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells

Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

Trends in cell medicine: from autologous cells to allogeneic universal-use cells for adoptive T-cell therapies

A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells